Oxlumo

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
II/0022	Update of section 4.8 of the SmPC in order to add "hypersensitivity" to the list of adverse drug reactions (ADRs) with frequency "Not known" based on post marketing safety data and literature. In addition, the MAH has taken the opportunity to update the Product Information (PI) to align with the	14/11/2024		SmPC and PL	SmPC new text Section 4.8 was updated to "hypersensitivity" to the list of adverse drug reactions (ADRs) with frequency "Not known". This update is based on post marketing safety data and literature. For more information, please refer to the Summary of

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	revised QRD template (version 10.4) and to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				Product Characteristics.
II/0021	Update of sections 4.8 and 5.1 of the SmPC in order to include information on the End-of Study safety (patient years of exposure) and efficacy of lumasiran in patients with Primary Hyperoxaluria Type 1 (PH1) based on final results from study ALN-GO1-003 (ILLUMINATE) listed as a category 3 study in the RMP; this is a phase 3 randomized, double-blind placebo-controlled study with an extended dosing period to evaluate the efficacy and safety of lumasiran in children and adults with PH1. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. Minor additional changes and deletions have been implemented after submitting comments on the proposed PI after the first phase of evaluation. The revisions proposed by the CHMP have been accepted by the MAH, and the additional changes proposed are considered adequate. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	14/11/2024		SmPC and PL	SmPC new text Section 4.8 of the SmPC was updated to include long-term safety data based on the final results from a category 3 study (study ALN-GO1-003). This study also provided data to update section 5.1 of the SmPC. For more information, please refer to the Summary of Product Characteristics.

PSUSA/10884 /202311	Periodic Safety Update EU Single assessment - lumasiran	13/06/2024	n/a		PRAC Recommendation - maintenance
IB/0020	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	31/05/2024	n/a		
IA/0019/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	27/02/2024	n/a		
II/0017	Submission of the final report from study ALN-GO1-002 (Study 002), listed as a category 3 study in the RMP. This is a phase 2, multicenter, open-label, extension study to evaluate the long-term administration of ALN-GO1 in patients with primary hyperoxaluria type 1. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	08/02/2024	n/a		

IB/0016	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	10/10/2023	n/a		
PSUSA/10884 /202211	Periodic Safety Update EU Single assessment - lumasiran	08/06/2023	n/a		PRAC Recommendation - maintenance
II/0014	Update of section 5.3 of the SmPC in order to update non-clinical information based on final results from study ALN-GO1; this is a 105-week s.c. Carcinogenicity Study in Rats with Toxicokinetics. In addition, the MAH took the opportunity to implement editorial changes and to bring the PI in line with the latest QRD template version 10.3. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	25/05/2023	18/10/2023	SmPC and PL	SmPC new text Section 5.3 of the SmPC was amended to remove information on carcinogenicity studies. For more information, please refer to the Summary of Product Characteristics.
IB/0015/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	04/04/2023	n/a		

IAIN/0012/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	06/01/2023	n/a		
PSUSA/10884 /202205	Periodic Safety Update EU Single assessment - lumasiran	01/12/2022	n/a		PRAC Recommendation - maintenance
IA/0011	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor	07/11/2022	n/a		

	changes to an approved test procedure				
II/0008	Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to clarify administration instructions, include a caution warning for the treatment of severely renally impaired patients, update the description of adverse reactions injection site reactions, abdominal pain and immunogenicity, update efficacy, pharmacokinetic information based on interim results from a category 3 study in the RMP ILLUMINATE-C (ALN-GO1-005): A single arm study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) and, in additon, based on available long-term efficacy and safety data from ongoing phase 3 studies ALN-GO1-003 in PH1 patients >6 years old and ALN-GO1-004 in PH1 patients <6 years old, and open-label extension study ALN-GO1-002. The Package Leaflet is updated accordingly. The RMP version 1.3 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	15/09/2022	18/10/2023	SmPC and PL	
PSUSA/10884 /202111	Periodic Safety Update EU Single assessment - lumasiran	10/06/2022	n/a		PRAC Recommendation - maintenance
II/0007	Update of section 5.3 of the SmPC in order to update the non-clinical information based on the final results from the 26-week GLP carcinogenicity study of	09/12/2021	15/09/2022	SmPC and PL	There was no evidence of an increased incidence of neoplasia in the transgenic Tg-rasH2 mouse following repeated monthly administration of lumasiran for 26 weeks

	lumasiran by s.c. injection in TgRasH2 mice, as agreed as part of protocol assistance (EMEA/H/SA/4014/2/2019/PA/PR/I). In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				at doses of 150, 500 or 1500 mg/kg.
PSUSA/10884 /202105	Periodic Safety Update EU Single assessment - lumasiran	02/12/2021	n/a		PRAC Recommendation - maintenance
IA/0006	A.6 - Administrative change - Change in ATC Code/ATC Vet Code	25/08/2021	15/09/2022	SmPC	
IA/0005	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	20/08/2021	n/a		
IB/0003	B.II.g.5.b - Implementation of changes foreseen in an approved change management protocol - Requires further supporting data	23/06/2021	n/a		
IB/0002	B.I.e.5.b - Implementation of changes foreseen in an approved change management protocol - Requires further supportive data	17/06/2021	n/a		
IB/0001/G	This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished	11/03/2021	n/a		

	product - Other changes to a test procedure (including replacement or addition) B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation				